CompletedPhase 2NCT04077736
Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
Studying Relapsing polychondritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peking University People's Hospital
- Principal Investigator
- Li ZhanguoPeking University Institute of Rheuamotology and Immunology
- Intervention
- Interleukin-2(drug)
- Enrollment
- 10 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2019 – 2023
Study locations (1)
- Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04077736 on ClinicalTrials.govOther trials for Relapsing polychondritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06941376An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing PolychondritisUniversity of Pennsylvania
- RECRUITINGPHASE1, PHASE2NCT06873100Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing PolychondritisPeking University People's Hospital
- RECRUITINGNCT04919538Longitudinal Study for Relapsing PolychondritisUniversity of Pennsylvania